How much revenue did Molecular Partners generate this year?
Molecular Partners has achieved a revenue of 14.28 M CHF this year.
Molecular Partners Revenue 2024
Molecular Partners Revenue
14.28 M CHF
Ticker
MOLN.SW
ISIN
CH0256379097
WKN
A12DEH
In 2024, Molecular Partners's sales reached 14.28 M CHF, a 102.9% difference from the 7.04 M CHF sales recorded in the previous year.
The Molecular Partners Revenue history
| YEAR | REVENUE (undefined CHF) | GROSS MARGIN (%) |
|---|---|---|
| 2030e | 361.52 | 1,94 |
| 2029e | 218.08 | 3,22 |
| 2028e | 82.57 | 8,51 |
| 2027e | 45.8 | 15,35 |
| 2026e | 18.36 | 38,28 |
| 2025e | 18.87 | 37,24 |
| 2024e | 14.28 | 49,22 |
| 2023 | 7.04 | 99,86 |
| 2022 | 189.6 | 99,47 |
| 2021 | 9.75 | 99,38 |
| 2020 | 9.34 | 93,99 |
| 2019 | 20.38 | 99,75 |
| 2018 | 10.36 | 79,70 |
| 2017 | 20.02 | 99,70 |
| 2016 | 23.04 | 99,74 |
| 2015 | 29.12 | 96,00 |
| 2014 | 26.63 | 99,32 |
| 2013 | 32.42 | 96,24 |
Molecular Partners Revenue, EBIT, Net Income CH0256379097 · A12DEH
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Molecular Partners, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Molecular Partners from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Molecular Partners’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Molecular Partners. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Molecular Partners’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Molecular Partners’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Molecular Partners’s growth potential.
Molecular Partners Revenue, EBIT and net profit per share
| Date | Molecular Partners Revenue | Molecular Partners EBIT | Molecular Partners Net Income |
|---|---|---|---|
| 2030e | 361.52 M CHF | 187.05 M CHF | 118.45 M CHF |
| 2029e | 218.08 M CHF | 135.97 M CHF | 13.16 M CHF |
| 2028e | 82.57 M CHF | -49.96 M CHF | -39.49 M CHF |
| 2027e | 45.8 M CHF | -68.69 M CHF | -57.58 M CHF |
| 2026e | 18.36 M CHF | -86.5 M CHF | -74.49 M CHF |
| 2025e | 18.87 M CHF | -71.91 M CHF | -62.81 M CHF |
| 2024e | 14.28 M CHF | -64.26 M CHF | -57.39 M CHF |
| 2023 | 7.04 M CHF | -61.11 M CHF | -61.98 M CHF |
| 2022 | 189.6 M CHF | 116.61 M CHF | 117.85 M CHF |
| 2021 | 9.75 M CHF | -63.42 M CHF | -63.79 M CHF |
| 2020 | 9.34 M CHF | -58.33 M CHF | -62.76 M CHF |
| 2019 | 20.38 M CHF | -36.66 M CHF | -36.29 M CHF |
| 2018 | 10.36 M CHF | -37.41 M CHF | -37.04 M CHF |
| 2017 | 20.02 M CHF | -25.84 M CHF | -25.43 M CHF |
| 2016 | 23.04 M CHF | -19.49 M CHF | -18.61 M CHF |
| 2015 | 29.12 M CHF | -2.22 M CHF | -149,000 CHF |
| 2014 | 26.63 M CHF | 1.84 M CHF | -2.28 M CHF |
| 2013 | 32.42 M CHF | 7.12 M CHF | 7.14 M CHF |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 32.42 M CHF | 7.12 M CHF | 7.14 M CHF |
| 2014 | 26.63 M CHF | 1.84 M CHF | -2.28 M CHF |
| 2015 | 29.12 M CHF | -2.22 M CHF | -149,000 CHF |
| 2016 | 23.04 M CHF | -19.49 M CHF | -18.61 M CHF |
| 2017 | 20.02 M CHF | -25.84 M CHF | -25.43 M CHF |
| 2018 | 10.36 M CHF | -37.41 M CHF | -37.04 M CHF |
| 2019 | 20.38 M CHF | -36.66 M CHF | -36.29 M CHF |
| 2020 | 9.34 M CHF | -58.33 M CHF | -62.76 M CHF |
| 2021 | 9.75 M CHF | -63.42 M CHF | -63.79 M CHF |
| 2022 | 189.6 M CHF | 116.61 M CHF | 117.85 M CHF |
| 2023 | 7.04 M CHF | -61.11 M CHF | -61.98 M CHF |
| 2024e | 14.28 M CHF | -64.26 M CHF | -57.39 M CHF |
| 2025e | 18.87 M CHF | -71.91 M CHF | -62.81 M CHF |
| 2026e | 18.36 M CHF | -86.5 M CHF | -74.49 M CHF |
| 2027e | 45.8 M CHF | -68.69 M CHF | -57.58 M CHF |
| 2028e | 82.57 M CHF | -49.96 M CHF | -39.49 M CHF |
| 2029e | 218.08 M CHF | 135.97 M CHF | 13.16 M CHF |
| 2030e | 361.52 M CHF | 187.05 M CHF | 118.45 M CHF |
Molecular Partners stock margins CH0256379097 · A12DEH
The Molecular Partners margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Molecular Partners. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Molecular Partners.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Molecular Partners's sales revenue. A higher gross margin percentage indicates that the Molecular Partners retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Molecular Partners's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Molecular Partners's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Molecular Partners's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Molecular Partners. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Molecular Partners's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Molecular Partners Margin History
| Molecular Partners Gross margin | Molecular Partners Profit margin | Molecular Partners EBIT margin | Molecular Partners Profit margin |
|---|---|---|---|
| 2030e | 99.86 % | 51.74 % | 32.76 % |
| 2029e | 99.86 % | 62.35 % | 6.03 % |
| 2028e | 99.86 % | -60.5 % | -47.82 % |
| 2027e | 99.86 % | -150 % | -125.74 % |
| 2026e | 99.86 % | -471.11 % | -405.7 % |
| 2025e | 99.86 % | -381.08 % | -332.84 % |
| 2024e | 99.86 % | -450 % | -401.88 % |
| 2023 | 99.86 % | -868.26 % | -880.7 % |
| 2022 | 99.47 % | 61.5 % | 62.16 % |
| 2021 | 99.38 % | -650.17 % | -653.94 % |
| 2020 | 93.99 % | -624.21 % | -671.7 % |
| 2019 | 99.75 % | -179.86 % | -178.03 % |
| 2018 | 79.7 % | -361.27 % | -357.66 % |
| 2017 | 99.7 % | -129.12 % | -127.05 % |
| 2016 | 99.74 % | -84.57 % | -80.78 % |
| 2015 | 96 % | -7.62 % | -0.51 % |
| 2014 | 99.32 % | 6.91 % | -8.56 % |
| 2013 | 96.24 % | 21.96 % | 22.02 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 96.24 % | 21.96 % | 22.02 % |
| 2014 | 99.32 % | 6.91 % | -8.56 % |
| 2015 | 96 % | -7.62 % | -0.51 % |
| 2016 | 99.74 % | -84.57 % | -80.78 % |
| 2017 | 99.7 % | -129.12 % | -127.05 % |
| 2018 | 79.7 % | -361.27 % | -357.66 % |
| 2019 | 99.75 % | -179.86 % | -178.03 % |
| 2020 | 93.99 % | -624.21 % | -671.7 % |
| 2021 | 99.38 % | -650.17 % | -653.94 % |
| 2022 | 99.47 % | 61.5 % | 62.16 % |
| 2023 | 99.86 % | -868.26 % | -880.7 % |
| 2024e | 99.86 % | -450 % | -401.88 % |
| 2025e | 99.86 % | -381.08 % | -332.84 % |
| 2026e | 99.86 % | -471.11 % | -405.7 % |
| 2027e | 99.86 % | -150 % | -125.74 % |
| 2028e | 99.86 % | -60.5 % | -47.82 % |
| 2029e | 99.86 % | 62.35 % | 6.03 % |
| 2030e | 99.86 % | 51.74 % | 32.76 % |
Molecular Partners Aktienanalyse
What does Molecular Partners do?
Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Molecular Partners's Sales Figures
The sales figures of Molecular Partners originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Molecular Partners’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Molecular Partners's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Molecular Partners’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Molecular Partners stock
How much was the turnover of the company Molecular Partners compared to the previous year?
The revenue of Molecular Partners has increased by 102.9% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Molecular Partners?
The revenue of Molecular Partners is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Molecular Partners measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Molecular Partners so important for investors?
The revenue of Molecular Partners is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Molecular Partners pay?
Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.
What is the dividend yield of Molecular Partners?
The current dividend yield of Molecular Partners is .
When does Molecular Partners pay dividends?
Molecular Partners pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Molecular Partners?
Molecular Partners paid dividends every year for the past 0 years.
What is the dividend of Molecular Partners?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Molecular Partners located?
Molecular Partners is assigned to the 'Health' sector.
Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Molecular Partners from 9/22/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.
When did Molecular Partners pay the last dividend?
The last dividend was paid out on 9/22/2024.
What was the dividend of Molecular Partners in the year 2023?
In the year 2023, Molecular Partners distributed 0 CHF as dividends.
In which currency does Molecular Partners pay out the dividend?
The dividends of Molecular Partners are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Molecular Partners
Our stock analysis for Molecular Partners Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Molecular Partners Revenue
- Molecular Partners Net Income
- Molecular Partners P/E
- Molecular Partners P/S
- Molecular Partners EBIT
- Molecular Partners Dividend
- Molecular Partners Stocks
- Molecular Partners Market capitalization
- Molecular Partners Debt
- Molecular Partners Liabilities
- Molecular Partners Equity
- Molecular Partners AAQS
- Molecular Partners Employees
- Molecular Partners ROE
- Molecular Partners ROA
- Molecular Partners ROCE
